Navigation Links
Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
Date:10/2/2007

proved glucose control and reduced levels of blood triglycerides without producing hypoglycemia. In addition, treatment with ISIS 325568 led to an increase in circulating glucagon-like peptide, or GLP-1, which is a hormone that helps to preserve pancreatic function, thereby enhancing insulin secretion.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis' collaboration with Ortho-McNeil, Inc., the discovery and development of drugs for diabetes and metabolic diseases, and the therapeutic potential of ISIS 325568 for Type 2 diabetes. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007
4. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
5. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
6. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Harvard medical expert internationally recognized as a leading ... decision last month to suspend Doug Barron for ... having the medical condition hypogonadism and ... unfair and discriminatory." ,, Hypogonadism is ... often referred to informally as Low T ...
(Date:12/15/2009)... -- Fenwal Inc., a global medical technology company ... availability, announced today that the U.S. Food and ... InterSol ® platelet additive solution. Fenwal ... specialized product used in combination with human plasma ... used to prevent or treat bleeding. ,, InterSol ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new market ... ,, Boehringer Ingelheim GmbH: PharmaVitae Profile ... Introduction ,, This analysis examines the ... in the Rx pharmaceutical sector. The profile ... and assessment of financial performance, with 1-6 ...
Breaking Medicine Technology:Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Heart Attacks Less Often Fatal Today 49550 1Heart Attacks Less Often Fatal Today 49550 2Heart Attacks Less Often Fatal Today 49550 3EUROPACE raises remote monitoring profile 49546 1EUROPACE raises remote monitoring profile 49546 2EUROPACE raises remote monitoring profile 49546 3Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 1Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 2
... 28 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) ... II field testing of its,anti-cancer drug, Rh-Apo2L. The ... intended to be a new drug therapy using ... is designed as a highly-targeted,therapy with direct function ...
... Initiate Phase III Program in First Half of ... Inc. (Nasdaq: IDEV ) today announced positive ... patients with acromegaly, a,disorder characterized by excessive blood ... factor 1 (IGF-1). The implant utilizes the Company,s,patented ...
Other Medicine Technology:Aida Announces Completion of Anti-Cancer Drug Phase Two Testing 2Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 2Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 3Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 4Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 5
(Date:12/15/2009)... Dec. 15 The failure of the ... to cut costs, much less the more effective ... the latest example of how big industry controls ... "The proposed drug amendment by Senator Dorgan (D-ND) ... Obama,s campaign pledge to allow Medicare to directly ...
(Date:12/15/2009)... -- Palo Alto Networks(TM), the network security company, ... PA-4000 Series next-generation firewalls for accurate threat prevention ... and control over applications such as peer-to-peer file ... university with eight facilities on five campuses. The ... number of academic schools and institutions throughout Japan. ...
(Date:12/15/2009)... couples of reproductive age were evaluated, Italian study found ... of children born with cystic fibrosis decreases when screening ... increases, a new study finds. , CF neonatal screening ... for many years. Since the 1990s, the area has ... infants born with CF. , Two different CF carrier ...
(Date:12/15/2009)... not delivered ,, WASHINGTON, Dec. 15 /PRNewswire-USNewswire/ ... ensure that healthcare reform does not override the ... companies in 37 states. ,, Prostate cancer screening ... population and individuals who are identifiable as high ... have a family history of prostate cancer. The ...
(Date:12/15/2009)... 15 Patient advocate ... Members of Congress that, "it doesn,t matter whether there,s ... - without a public option - give government authority ... also fund a new social agenda by shifting billions ... groups, newly arriving immigrants, and local politicians." ...
Breaking Medicine News(10 mins):Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2
... ALBUQUERQUE, N.M., Sept. 22 Biomoda, Inc.,(OTC Bulletin ... diagnostics company, expanded its intellectual property portfolio,with approval ... its Trademarks,CyDx(R) and CyPath(R)., "We are pleased ... for,our product portfolio," said John Cousins, Biomoda president. ...
... A study appearing in the Sept. 18 issue of ... among individuals with no colorectal neoplasia (abnormal growths) on initial ... low. The data provides support for rescreening at an interval ... , "This research is very significant as it is the ...
... radiosurgery (SRS) and whole brain radiation therapy (WBRT) for ... twice the risk of developing learning and memory problems ... research from The University of Texas M. D. Anderson ... randomized trial were presented at today,s 50th annual meeting ...
... Sept. 22 Stern + Associates (S+A), the,rapidly ... in central New Jersey with offices in Cambridge,Mass., ... roster: Biotest,Diagnostics Corporation and the Pain Control product ... addition, S+A expanded its public relations,programming for Bracco ...
... Johnson & Johnson, Ernst & Young, and,Kaplan Eduneering ... AdvaMed 2008,s list of,sponsors includes industry leaders, consulting ... the Ontario Ministry of Economic,Development & Trade (MEDT) ... number of sponsors increased this year by 52% ...
... with Social Security Disability Insurance as population ages; though disability ... , ... Belleville, Ill.(Vocus) September 22, ... retirement age, an echoing wave of the working population is ...
Other Medicine News:Health News:U.S. Patent Office Grants Biomoda Registration for Trademarks 2Health News:Risk of colorectal cancer extremely low 5 years after a normal colonoscopy screening 2Health News:Whole brain radiation increases risk of learning and memory problems in cancer patients 2Health News:Whole brain radiation increases risk of learning and memory problems in cancer patients 3Health News:Stern + Associates Signs New Clients to Health Care Practice 2Health News:AdvaMed 2008 Sponsor Participation Increases by 52% 2Health News:AdvaMed 2008 Sponsor Participation Increases by 52% 3Health News:AdvaMed 2008 Sponsor Participation Increases by 52% 4Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 2Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 3Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 4Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 5
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... trabeculum provides the highest magnification of ANY gonioscopy ... treating the trabecular meshwork. One 62° mirror ... angle while the central portion of the lens ... for signs of glaucoma and other central retinal ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
... AFX Lens is a direct ... in an air-filled eye. In ... a primary air-fluid exchange vitrectomy ... sutureless design make it well ...
Medicine Products: